Purpose
=======

Patients that suffer from metastatic castration resistant prostate cancer (mCRPC) had few treatment options for a long time [@B1]. During the last decade major progress has been made extending the treatment options considerably. New generation anti-hormonal agents (NAA; abiraterone (ABI), enzalutamide (ENZA)) new radiotherapeutics (alpharadin; radium-223) and a new taxan chemotherapy (cabazitaxel (CAB)) have all been approved and shown to be active after failure of docetaxel (DOC) as a 2^nd^ line therapy [@B2],[@B3],[@B4],[@B5],[@B6]. However, limited data are available to differentiate patients that may benefit rather from chemotherapy with CAB than from a NAA post DOC. Moreover, none of these substances have been investigated in 3^rd^ or 4^th^ line within a prospective randomized clinical trial, and there is concern regarding acquired cross resistances among them. Nevertheless, in real-world oncology many patients receive more than two treatment lines aiming at a cumulative survival benefit that has yet to be confirmed. Prospective trials with approved substances are rarely ever conducted. Hence, retrospective analyses might help to improve decision making and treatment processes for this relevant patient group.

The objective of this study was to analyze all patients from our comprehensive cancer center and private practice who received CAB either in 2^nd^ line or in later lines for clinical parameters associated with a response to CAB.

Methods
=======

In this retrospective observational study all 69 patients with mCRPC treated with CAB at the National Center of Tumor Diseases (NCT) and a private practice were identified and their records accessed through the electronic patients charts [@B7]. The project was approved by the local ethics committee.

Clinical parameters assessed included Gleason score (GS), tumor stage, location of metastases, time to castration resistance on androgen ablation therapy, type of 1^st^ line therapy, type of 2^nd^line therapy, response to 1^st^ line therapy and duration of response (prostate specific antigen (PSA) and radiographic) as well as response and duration of response to later lines of CAB.

Progression free survival (PFS) was evaluated using the Prostate Cancer Working Group 2 (PCWG2) criteria [@B8]. Side effects were classified according to CTCAE dictionary version 4.0. Overall survival (OS) was calculated from the date of start of systemic anti-hormonal treatment and the start of CAB treatment to the date of death or date of last follow-up (last assessed on March 2016). Survival and progression were calculated using Kaplan-Meier estimates and compared using log-rank tests. Associations between factors were evaluated using non-parametric Kendall-tau or Pearson correlation. Primary outcomes were the OS as well as the PFS since initiation of CAB. Secondary outcomes were PFS on 1^st^ line treatment as well as correlation analyses between treatment factors. Statistical analyses were conducted using the SPSS v21 software.

Results
=======

The final study population consisted of 69 patients that started systemic anti-hormonal LHRH analogue treatment between February 1998 and January 2015. Most of the patients received DOC as 1^st^ line therapy (n=52, 75.4%). Other 1^st^ line therapies included ABI (n=9), ENZA (n=4), ipilimumab (n=1, as part of a clinical trial), and PSMA ligands (n=3, as part of a clinical trial). In 2^nd^ line, patients received ABI (n=31), CAB (n=18), DOC (n=12), ENZA (n=5), RNA vaccine (n=1, as part of a clinical trial), and mitoxantrone (n=2). CAB was applied as 3^rd^ line treatment in 25 patients, as 4^th^ line therapy in 19 patients, as 5^th^line in 5 patients, and as 6^th^ line in 2 patients.

CAB was administered according to the protocol that was established by the Phase-III TROPIC trial in the majority of patients [@B1]. However, 17.3 % of patients received an upfront dose-reduction (i.e. 20% = 20 mg/m² qd22, n=9; \~30% = 17.5-18 mg/m² qd22, n=3) due to reduced general condition (ECOG 2 or ECOG 1 plus bone marrow dysfunction). Three patients were treated biweekly analogue the Prosty II trial protocol [@B9]. Six patients received CAB on a weekly scheme. In four cases dose reductions were necessary after cycles 1 (n=2), 2 (n=1) and 6 (n=1) due to bicytopenia, respectively. All patients received CAB in 4^th^ line. In 3 patients, CAB regime was changed from three-weekly to weekly after cycle 1 due to bicytopenia. Those patients had received CAB in 3^rd^, 4^th^ and 6th treatment line. Treatment was generally well tolerated with an average of 5 cycles (range 1-11) and a treatment duration of 3.6 months (range 0.4-17.0). Treatment was discontinued in most cases either due to progressive disease or when anticipated cycles of CAB had been applied. In one case CAB treatment was terminated due to patient preference. In four patients treatment was discontinued due to toxicity (neutropenic fever CTC 4° (n=2); acute renal insufficiency CTC 4° (n=1); peripheral sensory and motor neuropathy CTC 3° in an 88-years old individual (n=1)). Three CTC 5° side effects were noted: Two patients died in neutropenic sepsis (84-years old patient on cycle 1 day 11; 75-years old patient on cycle 2 day 11). A 71-years old patient died due to spontaneous subdural hematoma as a result of CAB-induced thrombocytopenia. Three patients are still on treatment. Patient characteristics are summarized in Table [1](#T1){ref-type="table"}.

Median time between the diagnosis of prostate cancer and the initiation of androgen deprivation was 2.0 months (95%CI 1.0-7.9). Median time to castration resistance was 35.0 months for all investigated patients (95%CI 26.0-43.0, Fig. [1](#F1){ref-type="fig"}a). Median PFS on 1^st^ line treatment was 7.0 months (95% CI 5.5-8.5, Fig. [1](#F1){ref-type="fig"}b). There were no significant differences regarding PFS on 1^st^ line treatment between DOC vs. any other treatment type or GS 6-7 vs. 8-10.

Median OS since start of CAB treatment was 10.0 months (95% CI 7.0-12.9). Median PFS on CAB treatment was 3.9 months (95% CI 3.0-4.8, Fig. [2](#F2){ref-type="fig"}a). There were no differences on OS and PFS on CAB stratified for GS (6-7 vs. 8-10), age at diagnosis, age at begin of CAB treatment, type of 1^st^ line therapy (DOC vs. any other), line of CAB (2^nd^ vs. any other; 2^nd^/ 3^rd^ vs. any other), and absolute PSA prior to CAB treatment (analyzed for percentile ranks 50; 66.7; 75) (data not shown). A PSA decline ≥ 50% was seen in n=20 patients receiving CAB (29.0%). A PSA reduction of at least 30% was noticed in n=24 patients (24.8%). PSA decline ≥ 50% on CAB showed a prolonged OS (16.6 months vs. 9.2 months; 95% CI 6.0-27.3; 6.2-12.2; p=0.087) and PFS (6.9 vs. 3.0 months, 95% CI 3.7- 10.2; 2.7-3.3; p= 0.09), however not statistically significant. Statistical significance was reached for the larger cohort with a PSA decline of at least 30% for OS (16.6 vs. 8.8 months; 95%CI 6.5-26.7; 6.2-11.4; p=0.039) and PFS (6.9 vs. 3.0 months; 95%CI 4.5-9.3; 2.7-3.3; p=0.03).

When stratified for PFS on 1^st^ line therapy (≤ 6 months vs. \> 6 months), patients with a PFS \> 6 months had a significantly longer PFS on CAB in any later treatment line that was 4.1 months vs. 3.0 months (95%CI 3.0-5.2; 2.2-3.8; p=0.021, Fig. [2](#F2){ref-type="fig"}b). No associations were noted between OS and duration of remission on 1^st^ treatment line. However, there was a trend towards longer OS on CAB treatment for patients that remained on remission on DOC \> 6 months (10.6 vs. 7.6 months; 95% CI 7.8-13.4; 4.4-10.8; p=0.051).

Patients with visceral metastases at time of CAB initiation had a significantly shorter PFS on CAB reaching 3.0 months vs. 5.8 months (95%CI 2.7-3.3; 3.2-8.4; p=0.014, Fig. [2](#F2){ref-type="fig"}c) and a shorter OS compared to those who only had bone or/and lymph node lesions (8.7 months vs. 11.7 months, 95% CI 5.9-11.5; 7.5-15.9; p=0.042, Fig. [2](#F2){ref-type="fig"}d) whereas PFS on 1^st^ line treatment did not differ significantly between those two groups.

Discussion
==========

Therapeutic options for mCRPC patients have been greatly expanded within the last couple of years. Beside NAAs, with CAB a novel taxane has also entered clinical practice [@B10],[@B11]. CAB has been approved for the treatment of mCRPC in the post-docetaxel setting as a 2^nd^ line treatment and is currently investigated within the FIRSTANA trial as 1^st^ line treatment option at different dose levels. However, in the real world CAB is often also used post ABI or ENZA as a 3^rd^ or 4^th^ line therapy being efficient in those settings [@B12],[@B13],[@B14],[@B15]. Retrospective single and multicenter experiences as well as meta-analyses have come to contradicting results for the optimal sequence of medication. While some showed no significant differences between the different agents used in 3^rd^ or 4^th^ line [@B16], others pointed to a survival benefit when applying the sequence DOC-CAB-ABI [@B14],[@B17],[@B18] or the sequence of CAB-NAA or vice versa compared to NAA-NAA post DOC [@B19]. However, no prospective randomized clinical trial has investigated treatment outcomes beyond 2^nd^ line and for different sequences. In addition, in the aftermath of the CHAARTED and STAMPEDE trials more and more patients will have received DOC in the hormone-sensitive setting raising new questions of optimal therapeutic approaches upon the development of castration resistant disease. In our retrospective cohort patients with a PFS longer than 6 months on 1^st^ line therapy had a significantly longer PFS on CAB irrespective of the line of treatment. Interestingly, it has been shown before, that cross resistance may exist between new anti-androgens and taxanes which is in accordance with our data [@B20],[@B21].

A high GS (as defined as 8-10) was not predictive for response to CAB as previously reported [@B22]. While previously published studies showed a correlation between longer duration of remission on first line DOC for higher GS [@B21],[@B23] we could not detect any such correlation for CAB in our cohort. We further found no correlation between the absolute level of PSA pre-CAB. While PSA increases during treatment for CRPC may be flare up phenomena and are not generally associated with radiographic progression [@B4], a PSA decline is in most studies associated with a better survival. We could also demonstrate that statistical significance for OS benefit was already reached with a PSA decline of at least 30%.

Large pooled retrospective analyses have revealed that the existence of visceral metastases is a negative prognostic factor associated with reduced OS of 13.3 months for patients with liver metastases and 19.4 months for patients with lung metastases [@B24],[@B25]. In our cohort, OS on CAB for patients with all types of visceral metastases was 8.7 months only. Interestingly, we also noted a significant difference in PFS on CAB in favor for patients with bone and/or bone and lymph node metastases compared to those with visceral metastases in our cohort (5.8 vs. 3.0 months). A difference in PFS was not observed in 1^st^ line treatment when stratified for visceral metastases. One explanation for the poor response of patients with visceral metastases could be that clonal selection associated with visceral spreading is associated with a more therapy-resistant phenotype, e. g neuroendocrine subtypes [@B26],[@B27]. Biopsies from visceral metastatic sites might help to further genetically characterize these clones and search for other treatment protocols. More prospective data are required to determine if CAB is a meaningful choice for mCRPC with visceral involvement.

We reported three grade 5 toxicities and several treatment discontinuations and dose modifications showing that CAB has substantial toxicity in this elderly and frail population. It should be noted that lower doses are equally effective with lower toxicity [@B28], [@B29] and should be considered as initial dose level.

Limitations to our study are its retrospective character, dual center data and small sample size that may have introduced a bias. These factors might explain the inability to detect survival differences due to to inadequate power in some analyses.

Clinical Practice Points
------------------------

The optimal treatment sequence for agents in mCRPC is still unknown. Prospective clinical trials are needed.

Conclusions
===========

Sequencing of new substances for mCRPC remains a subject of debate. CAB is approved for second line therapy following DOC. However, it is also used following new anti-hormonal treatments or in later lines. In our analysis CAB seems to be active in all these indications, especially if the tumor was sensitive to any 1^st^ line treatment, irrespective of the line of treatment when CAB was being deployed. However, patients with visceral metastases had a significantly shorter OS and PFS on CAB. Prospective studies are needed to identify the optimal treatment sequence for patients with mCRPC.
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ABI

:   abiraterone

CAB

:   cabazitaxel

DOC

:   docetaxel

ENZA

:   enzalutamide

GS

:   Gleason score

mCRPC

:   metastatic castration resistant prostate cancer

NAA

:   new generation anti-hormonal agent

OS

:   overall survival

PFS

:   progression free survival

PSA

:   prostate specific antigen

PSMA

:   prostate specific membrane antigen

![**a)** Time between initiation of systemic LHRH treatment and the development of castration resistant disease was 35.0 months. **b)** PFS on 1^st^ line treatment independent of treatment type was 7.0 months.](jcav08p0507g001){#F1}

![**a)** Progression free survival (PFS) on cabazitaxel (CAB) as 2^nd^ or later line treatment; median PFS was 3.9 months. **b)**PFS on CAB stratified for PFS on 1^st^ line (≤ 6 months vs. \> 6 months). Patients with PFS~1st\ line~\> 6 months had a significantly longer PFS on CAB in any later treatment line (4.1 months vs. 3.0; p=0.021). **c)**PFS of patients with visceral metastases was 3.0 compared to 5.8 months when no visceral metastases were present (p=0.014). **d)**Overall survival (OS) of patients with visceral metastases was 8.7 compared to 11.7 months in the absence of visceral metastases (p=0.042).](jcav08p0507g002){#F2}

###### 

Patient Characteristics.

  Parameter                                                    No.           \% (Range)
  ------------------------------------------------------------ ------------- --------------
  **Total number of patients**                                 69            100
  **Age at diagnosis \[years\], median**                       62            (46 - 81)
  **Age at CAB \[years\], median**                             69            (51 - 88)
  **Gleason Score at first diagnosis**                                       
  6-7                                                          27            39.1
  8-10                                                         42            60.9
  **Clinical nodal status at first diagnosis**                               
  N0                                                           32            46,4
  N1                                                           33            47,8
  missing                                                      4             5,8
  **Metastatic spread (prior to CAB treatment)**                             
  bone metastases                                              59            85.5
  peritoneal metastases                                        4             5.8
  lung metastases                                              14            20.3
  liver metastases                                             24            34.8
  brain metastases                                             3             4.3
  adrenal gland metastases                                     8             11.6
  **CAB treatment cycles, median**                             5             (1-11)
  **Duration on CAB, median**                                  3.6           (0.4-17.0)
  **CAB regime**                                                             
  25 mg/m², qd21                                               42            60.8
  20 mg/m², qd21                                               9             13.0
  17.5 -18.0 mg/m², qd21                                       3             4.3
  16 mg/m², qd15                                               3             4.3
  10 mg/m², qd8                                                6             8.7
  unknown                                                      6             8.7
  **Type of first line treatment**                                           
  Docetaxel                                                    52            75.4
  Abiraterone                                                  9             13.0
  Enzalutamid\*                                                4             5.8
  PSMA ligand\*                                                3             4.3
  Ipilimumab (within clinical trial)                           1             1.4
  **Type of 2nd line treatment**                                             
  Docetaxel                                                    12            17.4
  Abiraterone                                                  31            44.9
  Enzalutamid                                                  5             7.2
  CAB                                                          18            26.1
  Mitoxantron                                                  2             2.9
  RNA vaccine\* (within clinical trial)                        1             1.1
  **CAB sequence**                                                           
  2^nd^ line                                                   18            26.1
  3^rd^ line                                                   25            36.2
  4^th^ line                                                   19            27.5
  5^th^ line                                                   5             7.2
  6^th^ line                                                   2             2.9
  **Mean PSA at initial diagnosis**                            96.2 ng/ ml   (0.1-900.0)
  **Mean PSA at time point of castration resistance**          68.5 ng/ ml   (0.6-355.0)
  **Mean PSA at time point of CAB begin**                      453.0 ng/ml   (0.0-5102.0)
  **Mean PSA at time point of progressive disease post-CAB**   478.8 ng/ml   (0.0-5074.0)
  **PSA response in treatment period**                                       
  ≥ 30%                                                        24            34.8
  ≥ 50%                                                        20            29.0
  ≥ 90%                                                        4             5.8

**Abbreviations:**CAB: cabazitaxel; PSA: prostate specific antigen; PSMA: prostate specific membrane antigen.
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